DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTGet Free Report) in a research report issued on Friday. The firm set a “hold” rating on the stock.

A number of other analysts also recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th. HC Wainwright lifted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

View Our Latest Analysis on DBV Technologies

DBV Technologies Stock Performance

Shares of DBVT stock opened at $4.47 on Friday. The company has a market capitalization of $91.95 million, a PE ratio of -0.99 and a beta of 0.64. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.49. The business’s fifty day moving average is $3.43 and its 200 day moving average is $3.84.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.

Featured Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.